

Title (en)
LINKED CYCLITOLS AND THEIR POLYSULFATED DERIVATIVES

Title (de)
VERKNÜPFTE CYCLITOLE UND DEREN POLYSULFATIERTE DERIVATE

Title (fr)
CYCLITOLS LIES ET LEURS DERIVES POLYSULFATES

Publication
EP 1412320 A4 20060125 (EN)

Application
EP 02742526 A 20020704

Priority
• AU 0200884 W 20020704
• AU PR612801 A 20010704
• AU PS196902 A 20020426

Abstract (en)
[origin: WO03004454A1] The invention relates to compounds of the following formula (I). In these compounds, R>1<, R>2<, R>3< and R>4< are each independently a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms, or hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, alkyloxycarbonyl, or alkylaminocarbonyl. At least two of R>1<, R>2<, R>3< and R>4< comprise the substituted or unsubstituted cyclitol. The linker can be any one of the following: -(CH2)>w<-, -(CH2)>x<-C6H4-(CH2)>x<-, -(CH2)>y<-NR5- (CH2)>y<-, and -(CH2)>z<-HCR6-(CH2)>z<-; wherein: w, x, y and z are independently an integer having a value of 0-10; R>5< is a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms; and, R>6< is -OH, -OSO>3<Na, -OSO>3<Na substituted with alkyl, cycloalkyl or aryl, or substituted or unsubstituted alkyl, cycloalkyl or aryl. The compounds can also include substituted or unsubstituted cyclitol carbamides with the linker bond at the carbamide nitrogen. In other embodiments, the invention provides pharmaceutical compositions which include the compounds, and use of the compounds in the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation and/or coagulation/thrombosis.
[origin: WO03004454A1] The invention relates to compounds of the following formula (I). In these compounds, R1, R2, R3 and R4 are each independently a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms, or hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, alkyloxycarbonyl, or alkylaminocarbonyl. At least two of R1, R2, R3 and R4 comprise the substituted or unsubstituted cyclitol. The linker can be any one of the following: -(CH2)w-, -(CH2)x-C6H4-(CH2)x-, -(CH2)y-NR5- (CH2)y-, and -(CH2)z-HCR6-(CH2)z-; wherein: w, x, y and z are independently an integer having a value of 0-10; R5 is a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms; and, R6 is -OH, -OSO3Na, -OSO3Na substituted with alkyl, cycloalkyl or aryl, or substituted or unsubstituted alkyl, cycloalkyl or aryl. The compounds can also include substituted or unsubstituted cyclitol carbamides with the linker bond at the carbamide nitrogen. In other embodiments, the invention provides pharmaceutical compositions which include the compounds, and use of the compounds in the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation and/or coagulation/thrombosis.

IPC 1-7
C07C 215/20; **C07C 215/26**; **C07D 317/46**; **A61K 31/133**; **A61K 31/335**; **A61K 31/165**; **A61K 31/137**; **A61P 7/02**; **A61P 9/00**; **A61P 35/00**

IPC 8 full level
A61K 31/133 (2006.01); **A61K 31/215** (2006.01); **A61K 31/255** (2006.01); **A61P 7/02** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 11/06** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 37/06** (2006.01); **C07B 61/00** (2006.01); **C07C 213/04** (2006.01); **C07C 215/44** (2006.01); **C07C 231/10** (2006.01); **C07C 235/40** (2006.01); **C07C 305/10** (2006.01); **C07D 317/46** (2006.01)

CPC (source: EP)
A61P 7/02 (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 11/06** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **A61P 37/06** (2017.12); **C07C 215/44** (2013.01); **C07C 305/10** (2013.01); **C07D 317/46** (2013.01); **C07C 2601/16** (2017.04)

Citation (search report)
• [A] X. XIE ET AL, J. BIOL. CHEM., vol. 275, no. 44, 2000, pages 34818 - 34825, XP001031395
• [AD] B.J. PAUL ET AL, SYNTHESIS, no. 6, 2001, pages 952 - 956, XP002356262
• [A] J. CHEM. SOC., PERKIN TRAN. 1, T. HUDLICKY ET AL, no. 12, 1991, pages 2907 - 2918, XP008056072
• See references of WO 03004454A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)
WO 03004454 A1 20030116; EP 1412320 A1 20040428; EP 1412320 A4 20060125; JP 2004532898 A 20041028

DOCDB simple family (application)
AU 0200884 W 20020704; EP 02742526 A 20020704; JP 2003510422 A 20020704